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Gastro-intestinal (GI) microbiota and the ‘gut-brain axis’ are proving to be increasingly 
relevant to early brain development and the emergence of psychiatric disorders. This review 
focuses on the influence of the GI tract on Brain-Derived Neurotrophic Factor (BDNF) and 
its relationship with receptors for N-methyl-D-aspartate (NMDAR), as these are believed to 
be involved in synaptic plasticity and cognitive function. NMDAR may be associated with 
the development of schizophrenia and a range of other psychopathologies including 
neurodegenerative disorders, depression and dementias. An analysis of the routes and 
mechanisms by which the GI microbiota contribute to the pathophysiology of BDNF-induced 
NMDAR dysfunction could yield new insights relevant to developing novel therapeutics for 
schizophrenia and related disorders. In the absence of GI microbes, central BDNF levels are 
reduced and this inhibits the maintenance of NMDAR production. A reduction of NMDAR 
input onto GABA inhibitory interneurons causes disinhibition of glutamatergic output which 
disrupts the central signal-to-noise ratio and leads to aberrant synaptic behaviour and 
cognitive deficits. Gut microbiota can modulate BDNF function in the CNS, via changes in 
neurotransmitter function by affecting modulatory mechanisms such as the kynurenine 
pathway, or by changes in the availability and actions of short chain fatty acids (SCFAs) in 
the brain. Interrupting these cycles by inducing changes in the gut microbiota using 
probiotics, prebiotics or antimicrobial drugs has been found promising as a preventative or 
therapeutic measure to counteract behavioural deficits and these may be useful to supplement 
the actions of drugs in the treatment of CNS disorders.   
 
 





The gut-brain axis 
     In humans the influence of the gastrointestinal (GI) tract on the brain has been noted since 
the nineteenth century. Recent analysis indicates a bidirectional route of communication 
between the GI tract and the CNS, termed the 'gut-brain axis' [1]which may have profound 
effects on CNS development and on aspects of behaviour relevant to normal and pathological 
cognitive function.   
     There are neuronal and hormonal contributions to the gut-brain axis [2,3]. Although the 
vagus nerve has both sensory and motor components, the majority of these are afferent, 
highlighting the importance of gut feedback by the vagus nerve in gut-to-brain 
communication. 
   The hormonal component is mediated via the hypothalamic-pituitary-adrenal axis which 
affects the gut through its mediation of stress responses and which can be programmed in 
early life [4-6]. The intestinal microbiota can be altered in response to psychological and 
physical stressors and this correlates with an increased susceptibility to disease [7-9]. In 
response to stress, corticotrophin-releasing hormone, produced in the paraventricular nucleus 
of the hypothalamus, initiates a cascade of events culminating in the release of cortisol from 
the adrenal glands. Cortisol can affect gut permeability by modulating the function and 
composition of the intestinal mucosal barrier, [10,11] altering the composition of the 
microbiome and causing dysbiosis [12,13]. The intestinal barrier is normally considered to 
comprise the microbiota, lining mucus layer, epithelial columnar cells together with the 
goblet cells admixed amongst them, and the internal lamina propria which provides a home to 
several types of immune system cells [14]. Between the epithelial cells (enterocytes) there are 
junctional complexes consisting of tight junctions and desmosomes which provide a 
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selectively permeable barrier restricting the passage of unwanted compounds [14,15]. These 
narrow paracellular spaces are expanded when intestinal permeability becomes compromised 
(e.g. in response to cytokines) allowing larger molecules, dietary antigens and even microbes 
to cross the epithelium, [16,17] potentially triggering an immune reaction.  
     The increased bacterial translocation can have deleterious effects on the host and has been 
associated with depression [17]. Exposure to stress at an early stage, such as through maternal 
separation has revealed a long-term alteration in the microbiota and an increase in the activity 
of the hypothalamic-pituitary-adrenal axis [5,18,19].  This exaggerated stress response is also 
produced in germ-free (GF) mice and, interestingly, can be normalised by bacterial 
colonisation [4]. Compositional changes in gut microbiota (the relative amounts of various 
bacterial species) are also observed in adulthood on exposure to chronic stress, accompanied 
by an increase in cytokines [20]. 
    Indeed, much of the influence of the GI tract on behaviour may be the result of its content 
of micro-organisms – primarily over 100 species of bacteria - which account for around 90% 
of the cells in adult mammals [21]. Increasingly it appears that these prokaryotes can 
modulate human brain development and function [22-25]. Advances in sequencing 
technology and metagenomics have highlighted the significance of the enteric micro-
organisms, giving rise to the nomenclature 'microbiota-gut-brain axis' which is now often 
used synonymously with the former ‘gut-brain axis’. The highest density of microbes is 
found on the mucosal surface of the large intestine where a symbiotic relationship is forged 
between the host and bacteria at an early stage of postnatal development [25-27].  
   Dominant bacterial phylotypes in the gut include Bacteroidetes and Firmicutes [28] and it 
is bacteria such as these which provide a range of benefits to the host including, but not 
limited to: degradation of otherwise indigestible fibres, protection from pathogenic bacteria 
(e.g. through physical barrier formation), ‘training’ of the innate immune system [28] and 
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synthesising essential nutrients (e.g. vitamin K).  A particularly important nutrient is 
tryptophan, an amino acid essential for protein synthesis but which also sits at the head of 
pathways generating 5-hydroxytryptamine, melatonin and the multi-functional kynurenine 
metabolites including kynurenic acid, quinolinic acid and nicotinamide [29-31]. 
   Many of the tasks carried out by these bacteria are critical to normal body function and 
involve mechanisms which have not evolved in humans themselves [32]. While humans are 
unable to synthesise tryptophan, for example, it is generated in many bacteria [33]. Indeed 
there are also synthetic enzymes in bacteria for key metabolites of tryptophan with marked 
activity at NMDARs (quinolinic and kynurenic acids, discussed below). The tryptophan-
kynurenine pathway is therefore a strong candidate for a mechanism by which the GI 
microbiota can influence CNS function. 
    
GI microbiota and embryonic development 
   Embryological development can be highly influenced by maternal factors such as stress, 
diet and infection [34-40]. Therefore, any disruption in normal maternal behaviour may lead 
to alterations in the maternal gut microbiota during pregnancy resulting in the release of 
atypical metabolites which can in turn be detrimental to the developing foetus [41, 42].  
   As prenatal life was thought to constitute a period of sterility, the dynamic population of GI 
microbiota has been thought to be acquired postnatally, shortly after parturition [4, 43] from 
when it develops continuously throughout life with a compositional profile reflecting that of 
the mother as a result of mother-infant proximity and lactation [44].  Postnatal microbial 
colonisation is influenced by a variety of factors including type of delivery [45] and the 
surrounding environment. Vaginal delivery exposes the foetus to faecal and vaginal bacteria, 
whereas a Caesarean section would expose the foetus to skin bacteria. The initially maternal 
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signature of the neonatal microbiome develops into a unique population after approximately 
one year.   
    The discovery of bacteria in the pre-term uterus was shown to be linked to complications 
in pregnancy (such as preterm labour), often contributing to neonatal morbidity and mortality 
[46]. However, several studies have concluded that foetuses may come into contact with 
commensal microbes before birth [47] and this premature exposure could be pivotal in 
priming the immature immune system and brain development in healthy neonates. This 
modification to the prevalent dogma of exclusively postnatal colonisation has arisen from 
studies of the maternal placenta and foetal meconium. DNA originating from Lactobacillus 
and Bifidobacterium species was found in a significant majority of human placentae tested by 
Satokari et al. [47] which suggested maternal to foetal horizontal transfer in utero. Bacterial 
DNA contains unmethylated motifs which, if transferred to the foetus, could trigger an 
immune response and affect early development. 
     Thus, although the exact timing of initial exposure is controversial, it remains clear that 
pre- and postnatal microbial colonisation of the GI tract is a highly significant event. The 
peri-natal period is a critical one in neurodevelopment and the composition of the microbiota 
at this stage, predominantly Proteobacteria and Actinobacteria [48], is involved in 
developmental programming which can have life-long effects [49-53], especially since the 
late pre- and early post-natal period is known to contain several critical developmental 
windows, in which NMDA receptors play a key role [54-58]. 
     The ultimate composition of the gut microbiota is influenced by a number of factors 
including genetics [59], diet, antibiotic use and disease [60,61]. Although the microbial 
profile of an individual is unique, the relative abundance and distribution of microbes is 
similar in most healthy individuals, supporting the view that significant perturbations from 




Gut Microbiota and psychiatric disorders  
     There is a growing recognition of the influence of GI microbiota in depression, anxiety 
and autistic spectrum disorders [8, 62-69] as well as cognitive function [70]. Around 70-90% 
of patients with inflammatory bowel disease experience clinical depression and anxiety [71-
73]. A study utilising the maternal separation model in GF rats assessed the animals for 
depressive behaviour with a forced swim test [74]. In comparison to controls, these rats were 
found to possess heightened levels of corticotrophin-releasing hormone mRNA in the 
amygdala (associated with stress and anxiety) and displayed increased immobility during the 
test (indicative of depression). In addition, administration of a probiotic reversed these 
behavioural changes, implying that bacteria were able to modify the psychiatric state. 
   Children diagnosed with autism spectrum disorders have been found to possess an altered 
gut microbial composition, with a decrease in species of Bifidobacteria and an increase in 
Lactobacilli [75] and Bacteroidetes [76] species. It can be difficult to distinguish whether 
these modifications are the cause of the condition, a direct result of the condition, or whether 
they can be attributed to the atypical eating behaviour exhibited by many autistic children, 
but the result emphasises the potentially important changes of behaviour that can be 
dependent on GI factors. 
   Schizophrenia is classified as a major psychotic disorder which causes significant 
deviations in the perception, emotions and behaviour of an affected individual. Symptoms 
most commonly present during early adulthood are classified as positive (hallucinations and 
delusions), negative (social withdrawal and lack of motivation) or cognitive (learning deficits 
and impaired working memory). Research using genome wide association studies have 
uncovered thousands of single nucleotide polymorphisms which together are thought to 
account for approximately 30% of the risk of developing schizophrenia [77]. However, the 
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exact aetiology of schizophrenia remains elusive and it is clear that both genetic and 
environmental factors contribute to development of the condition.   Many schizophrenic 
patients also present with associated GI complaints, raising questions about whether the gut 
could be involved in the pathophysiology of the disorder which is generally attributed to 
aberrations of neurodevelopment and synaptic plasticity [78-80].  
   A number of studies have focused on the immunological pathway in schizophrenia as 
immune dysregulation is frequently seen in these patients [81-86] and genome wide 
association findings have identified a link between the risk of developing the condition and 
immune-related genes [87].  The microbiota interact with gut mucosal cells to induce the 
release of pro- and anti-inflammatory cytokines [20] and several studies have discovered an 
up-regulation of pro-inflammatory cytokines in individuals with schizophrenia. In chronic 
schizophrenia, pro-inflammatory interleukin-6 (IL-6) levels were found to be elevated and 
anti-inflammatory interleukin 10 (IL-10) levels were found to be reduced in comparison to 
controls [88]. This was corroborated by Song et al. [89] who also found an increase in IL-6, 
as well as raised serum levels of interleukin 1β (IL-1β) and tumour necrosis factor α (TNFα).  
The elevation of these pro-inflammatory cytokines demonstrates an up-regulated 
inflammatory status in schizophrenia patients and represents an additional mode of 
immunological, bi-directional brain-gut communication, with enteric microbes having the 
ability to affect brain function indirectly by altering circulating cytokine levels. 
     There are many links between the presence of obesity or diabetes and psychiatric 
disorders. One study suggested that an elevated white blood cell count could be utilised as a 
marker for the systemic inflammation which is characteristic of schizophrenia, with a higher 
count being related to a greater risk of developing metabolic syndrome, as well as predicting 
an increased severity of psychiatric symptoms [90]. Furthermore, anti-psychotic drugs have 
been shown to produce metabolic symptoms in rats. As shown by Davey et al. [91], gender-
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specific (female only) rapid weight gain and up-regulation of inflammatory cytokines were 
observed in rats treated with olanzapine. The observed increase in weight is a well-known 
side effect of anti-psychotic medication in humans which often negatively impacts patient 
compliance and, therefore, this is an important aspect of pharmaceuticals which must be 
targeted and improved. The effects of this weight gain could subsequently lead to metabolic 
syndrome, particularly the development of insulin resistance. The microbial profiles of both 
male and female rats in this study were also significantly altered, with an increase in 
Firmicutes and a decrease in Bacteroidetes species. 
 
Glutamate, NMDA and schizophrenia 
   The dominant theory in schizophrenia research for several decades involved abnormal 
dopamine levels and metabolism in the brain, particularly within the ventral striatal 
mesolimbic area and prefrontal cortex. This hypothesis arose from the discovery of the potent 
anti-psychotic action of dopamine antagonists which suggested that a hyper-dopaminergic 
state was involved in the aetiology of schizophrenia especially since atypical dopamine levels 
can influence processes involved in schizophrenia such as synaptic plasticity and associative 
learning [92]. More recently there has been a shift in research focus towards the fusion of 
genetic and environmental factors which subsequently affect the glutamatergic system during 
development, resulting in NMDAR dysfunction [81]. 
     NMDAR are involved in many aspects of early brain development and they provide a site 
at which a range of modulatory factors could influence brain formation and maturation [55-
58]. One example of this is the ability of tryptophan metabolites such as quinolinic acid (an 
agonist at NMDAR [93]) and kynurenic acid (an antagonist at all glutamate receptors [94]) to 
alter neuronal excitability via their effects on glutamate receptors [30, 31]. Inhibiting the 
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kynurenine pathway during pregnancy results in substantial changes to the structure, 
electrophysiological functionality and protein expression of the postnatal offspring [95-98].  
     It has been claimed that kynurenic acid is also able to block α7-nicotinic receptors at low 
concentrations [99] but this has been disproved by at least three independent laboratories 
which have failed to reproduce any nicotinic blockade [101-102]. 
     NMDARs are tetrameric, composed of two GluN1 sub-units (containing the glycine/D-
serine binding site) and two GluN2 sub-units (containing the glutamate/NMDA binding site). 
The receptors exist on both pre- and post-synaptic sites [103]. The GluN2A-containing 
receptors have been associated especially with synaptic locations where they are believed to 
function during brain development, while receptors which include the GluN2B-subunit often 
exist at extra-synaptic locations and act in opposition to those containing GluN2A subunits. 
Both can modulate synaptic transmission and neuronal viability, with the GluN2A-containing 
receptors promoting potentiation and protection from damage, while GluN2B subunit 
receptors are linked to synaptic depression and cell death [104]. Other sub-units also exist 
including GluN2C, GluN2D, GluN3A and GluN3B. Deletion of the Grin1 gene in 
hippocampal CA1 pyramidal cells results in adult mice which do not possess obvious 
developmental abnormalities, but lack the circuitry and long-term potentiation (LTP) 
mediated by NMDARs, leading to deficits in spatial memory [105]. The cognitive 
dysfunction seen in schizophrenia may be a result of a disrupted link between the activation 
of NMDARs, activity-dependent gene expression and neuroplasticity of interneurons [106]. 
     The NMDAR hypofunction model aims to explain the cognitive problems associated with 
schizophrenia. Abnormalities in dopamine signalling may be secondary to NMDAR 
dysfunction [107], since NMDARs regulate dopaminergic neurons and glutamate and 
dopamine signalling interact in order to transmit sensory information [108].  
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   NMDARs are important in GABA interneuron development and function, and 
abnormalities in receptors located on these interneurons are implicated in behavioural 
changes seen in schizophrenia [103].  Malfunction of NMDARs on fast-spiking inhibitory 
GABAergic interneurons within the limbic system causes a reduction in the tonic regulation 
of pyramidal neurons within the cerebral cortex. As a result of this disinhibition, there is 
increased firing and glutamatergic output. In addition, interneuron dysfunction negatively 
affects brain connectivity and integrative circuitry, which are compromised and lead to 
abnormal signal-to-noise ratios. As the ratio between the strength of desired transmission to 
that of unwanted interference is skewed towards an increase in background noise, there is an 
increase in uncoordinated impulse firing which is thought to provide a basis for the cognitive 
deficits observed in patients with schizophrenia [109].  
     Mice deficient in sub-unit GluN1 (5% of normal) display elevated motor activity and a 
reduction in social interactions [110]. In addition, a significant number of genes which 
underlie the genetic risk for developing schizophrenia impact NMDARs directly, or indirectly 
through signalling pathway components [54]. NMDAR antagonists, such as phencyclidine 
(PCP) and ketamine, cause schizophrenia-like symptoms including psychosis and cognitive 
dysfunction in healthy subjects, while exacerbating the symptoms of chronic schizophrenics. 
For example, PCP, a dissociative anaesthetic, was found to induce feelings of estrangement 
and hostility as well as disorganised thought in normal individuals, whereas pre-existing 
symptoms in schizophrenic patients were precipitated or enhanced [111]. Schizophreniform 
effects were exacerbated in animal models by persistent blockade of the receptors. 
Furthermore, a recent study investigating the effects of gut microbiota on the CNS reported a 
schizophrenia-like state in rats through subchronic PCP administration [112]. In response to 
this treatment, cognitive deficits measured through impaired novel object recognition were 
seen for up to three weeks in these rats, when compared to controls. These changes were 
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found to be associated with an altered gut microbiota population, (assessed by analysis of 
faecal samples), and cognitive disturbances were normalised by ampicillin treatment. These 
effects of a major antibiotic are consistent with the idea that specific symptoms of 
schizophrenia are a result of microbial disturbance and receptor malfunction. It should always 
be remembered, however, that the penicillin group of antibiotics have other, more direct 
pharmacological actions which can contribute to their effects on CNS function, including the 
modification of GABA-mediated neurotransmission and the actions of benzodiazepines [113-
116].  
   In contrast, agents which enhance the activity of NMDARs are able to significantly reduce 
these symptoms [117]. Levin et al. [118] investigated the effects of the NMDAR co-agonist 
D-serine in healthy human subjects at the glycine binding site of the receptor [119]. In order 
to interpret the findings in relation to changes in cognition, several behavioural and cognitive 
tests were employed: Visual Analogue Scales; Continuous Performance Test-Identical Pairs 
and Rey Auditory Verbal Learning Tests. Following administration of D-serine, there was a 
significant decrease in feelings of depression and anxiety in comparison to baseline and 
placebo measurements, as indicated through Visual Analogue scores. In addition, Continuous 
Performance Test-Identical Pairs and Rey Auditory Verbal Learning Test scores revealed an 
improvement in attention and information retention respectively post D-serine treatment. 
These findings show that increasing agonistic activity on NMDARs produces pro-cognitive 
and anti-psychotic effects which might be useful for treating a range of neuropsychiatric 
conditions including anxiety, depression, autistic disorders, schizophrenia, strokes and 
degenerative cognitive dysfunction.  The observations do, however, raise the question of 
whether NMDAR agonists or antagonists are likely to be of most use in these disorders. The 
problem has been contentious for many years with respect to neurodegeneration and the 
problem of whether acute or low dose activation of receptors is an appropriate treatment with 
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the risk that chronic or high dose treatments may induce calcium overload and exacerbate 
brain damage. In a similar fashion it is now clear that some NMDAR antagonists such as 
ketamine are not only anti-depressant, but are more rapidly efficacious than traditional 
monoamine-related treatments [120-122]. Interestingly, it has been suggested that BDNF is 
involved in the antidepressant activity of the NMDAR antagonist 7-chloro-kynurenic acid 
[123]. 
    
Brain-derived Neurotrophic Factor (BDNF) 
   BDNF is one of the most widely expressed and closely studied neurotrophins and is 
structurally related to nerve growth factor, neurotrophin-3 and neurotrophin-4, which regulate 
the viability and functional integrity of specific neuronal populations.  
   The synthesis of BDNF originates from a precursor protein, pre-pro-BDNF, which is 
translated in the rough endoplasmic reticulum. The signal peptide of this precursor is 
removed through endoproteolytic cleavage to produce pro-BDNF, and then again to produce 
BDNF in its mature state. Mature BDNF is then transported to post-synaptic dendrites in 
secretory granules or pre-synaptic terminals in vesicles [124]. There is controversy 
surrounding the location at which the last cleavage stage occurs, intracellularly [125] or 
extracellularly [126]. This is an extremely important debate to settle as pro- and mature 
BDNF have substantially different functions. Mature BDNF is involved in LTP induced by 
high frequency stimulation, whereas pro-BDNF is involved in long-term depression (LTD) 
induced by low-frequency stimulation [127].  The induction of LTP increases BDNF mRNA 
levels in CA1 hippocampal neurons whereas LTD can decrease BDNF secretion [128,129]. 
     BDNF is involved in a plethora of functions within the CNS including neuronal survival 
and differentiation [130] and changes in BDNF levels may contribute to the chemical and 
structural imbalances associated with schizophrenia through dysfunction of synaptic 
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transmission and plasticity leading to cognitive deficits [78]. Hippocampus-specific deletion 
of BDNF in mice leads to impairments in Novel Object Recognition and spatial learning, 
compared to controls [131]. Participation in exercise and increased consumption of niacin 
(vitamin B3) have been found to affect positively the synthesis of BDNF.  
   BDNF production  can occur through a constitutive pathway (spontaneous) or regulated 
pathway (in response to neural activity), with the latter being the predominant route [132]. 
BDNF signals through two membrane-bound receptors: p75 (the neurotrophin receptor) and 
TrkB (one of the tropomyosin-related kinase receptors) [133].  When activated by BDNF 
binding, TrkB undergoes dimerization and phosphorylation, with the resulting activation of 
mitogen-activated protein kinases; phospholipase C and phosphatidylinositol-3-kinase [132].  
   The Bdnf gene is expressed from early development throughout life and the diversity of 
roles which BDNF plays in the brain may be attributed to the complexity of its genomic 
structure [134] which includes at least eight 5’ exons and one 3’ exon with corresponding 
promoter regions [132]. The range of promoters leads to production of numerous BDNF 
transcripts which are distributed widely throughout the brain with high specificity. Long term 
effects of BDNF are mediated by gene expression, but interactions with effectors in the 
cytoplasm allow the neurotrophin to mediate short-term effects on neuron excitability and 
synaptic transmission [78].  
   There is a single nucleotide polymorphism in the human BDNF gene involving a valine to 
methionine amino acid substitution at position 66 (Val66Met) which impacts the packaging 
process of mature BDNF to secretory vesicles. This consequently decreases the activity-
dependent secretion of the neurotrophin [132] and may contribute to several psychotic 
disorders [135]. Mice with a single copy deletion of the BDNF gene were found to have 
significantly impaired learning when tested in the water maze and required training for twice 
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as long as wild type mice [136]. In addition, homozygous BDNF knockout mice are unable to 
sustain life due to gross neurodevelopmental and sensory defects [137]. 
    When compared to healthy individuals, the brains of patients with psychiatric conditions, 
including schizophrenia and bipolar disorder, have been found to possess decreased BDNF 
functionality. The full-length trkB receptor isoform trkB-TK+ is the primary mediator of  the 
effects of BDNF on neurotrophic properties and therefore constitutes a useful measure of 
BDNF activity in relation to neuropsychiatric disorders. Post mortem analysis of 
schizophrenic brains has revealed significantly lowered trkB-TK+ mRNA levels in the 
hippocampus compared with control brains [138]. 
 
The microbiota and BDNF 
     GI microbiota may have the ability to modulate behaviour via changes in BDNF 
production. BDNF levels are lower in the cortex and hippocampus of GF mice compared to 
controls suggesting that the GI microbiota played some role in elevating brain BDNF [4]. 
This theory is supported by the fact that colonisation of these sterile mice with faecal matter 
from specific pathogen-free (SPF) mice or probiotic administration, resulted in partial and 
complete normalisation of behaviour and BDNF levels respectively. 
    Heijtz et al. [25] also found that BDNF mRNA expression in the hippocampus, amygdala 
and cingulate cortex (neural areas involved in anxiety and fear) of GF mice was significantly 
lower than in SPF mice. In addition, expression of synaptophysin and Post-Synaptic Density-
95 in GF mice was higher than SPF mice in the striatum, suggesting that these proteins may 
also be subject to modulation by enteric bacteria. As these proteins are involved in synaptic 
vesicle maturation, their elevation may cause a potentiation of synaptic transmission leading 
to long-term changes and behavioural disorders in adults. GF mice exhibit a decrease in 
BDNF  mRNA [139] although only male mice displayed a significant decrease in mRNA 
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expression in the hippocampus. This is of particular interest as epidemiological data for 
schizophrenia reveal that the condition is more prevalent in males than females [140,141]. 
Gender specificity was not evident in immune or endocrine responses which, as expected, 
were diminished and exaggerated respectively in all the GF mice tested. 
   Despite these correlations Neufeld et al., [142] found that the absence of gut microbiota in 
GF mice had an anxiolytic effect in an elevated plus maze. An increase in hippocampal 
BDNF mRNA expression, specifically in the dentate gyrus region, was also recorded in GF 
mice compared to SPF animals. Use of the probiotic Bifidobacterium breve 6330 caused an 
increase in BDNF total splice variants but a decrease in BDNF splice variant IV in normal 
rats [143]. In addition to GF animals, this study also used rats stressed by maternal separation 
which were found to possess increased BDNF levels in the hippocampus, although 
administration of the probiotic had no effect in these animals.  
   The variations in results may stem from the use of different measures of BDNF such as 
RNA message, protein expression or biological activity, all of which are required ideally for a 
complete assessment of function. It is also important to note that each of these parameters 
may differ in different brain regions, animal age or gender even within the same species. 
 
Microbial regulation of BDNF and NMDARs  
      A link between stress, BDNF and NMDA receptors was described by Klug et al. [144] 
who observed that the administration of corticosterone, mimicking the effects of stress, on 
BDNF heterozygous mice (with around 50% of normal cerebral BDNF) altered the subunit 
composition of NMDA receptors in the hippocampus. Differential effects were seen in male 
and female mice with differences also between dorsal hippocampal regions concerned with 
learning and memory, and ventral regions involved more in fear and anxiety behaviour.  
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     A study looking at memory dysfunction found that GF mice, on exposure to Novel Object 
Recognition and T-maze exploration tests, lacked non-spatial and working memory [145] 
which are believed to involve NMDARs in the hippocampus [146-149]. In addition, the 
animals exhibited a decrease in hippocampal BDNF expression compared to colonised 
controls consistent with evidence that the microbiota can modulate cerebral neurotrophins 
[81]. These interactions indicate the importance of normal gut microbiota in linking BDNF 
and NMDA-dependent hippocampal memory. This impairment in cognitive function, 
associated with a reduction in BDNF levels, may therefore be preventable or treatable 
through manipulation of the bacterial populations or a direct restoration of BDNF activity.  
   The findings by Sudo et al. [4] not only revealed altered levels of BDNF in GF mice, but 
also found that the expression of NMDAR sub-unit GluN2A was decreased in GF mice 
compared to controls. As previously discussed, receptors with these sub-units are associated 
with potentiation of synaptic transmission and neural protection [104] and, therefore, a 
decrease in these sub-units could result in reduced synaptic potentiation and vulnerability to 
damage. Neufeld et al. [142], also discovered a reduction in the expression of NMDAR 
GluN2B sub-unit mRNA in the amygdala which strengthens the case that modulation of 
BDNF levels affects NMDAR function.  
      The activation of NMDARs promotes the synthesis of BDNF. The depolarisation-induced 
influx of calcium through voltage-gated Ca2+ channels (VGCCs) in hippocampal neurons 
[134] triggers the binding of transcription factors such as Ca2+  response factor (CaRF) and 
cyclic AMP response element binding protein to components of  the Bdnf gene [150].  
Conversely, BDNF acts on the NMDARs to increase excitatory synaptic transmission in 
cortical and hippocampal areas via the phosphorylation of GluN1 and GluN2B sub-units.  In 
hippocampal synaptoneurosomes, phosphorylation of the GluN1 subunit is demonstrable 
within 5 minutes [151], indicating a role for BDNF in the acute regulation of synaptic 
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transmission and plasticity. Additionally, on stimulation with BDNF, there is a differential 
up-regulation of protein and mRNA levels of GluN1, GluN2A and GluN2B sub-units in 
cultured hippocampal neurons [152]. BDNF stimulation also increased the cohort of sub-unit 
proteins associated with the plasma membrane and increased activity of the NMDAR, 
providing a potential explanation of why a deficiency in BDNF, as described in the brains of 
many schizophrenic patients [153-155] can cause dysfunction of NMDARs. A different view 
arises from observations demonstrating an inhibitory effect of BDNF on NMDA-mediated 
excitotoxicity in normal [156] or Huntington's disease model animals [157], perhaps 
reflecting the reduced receptor function that can occur as a result of over-stimulation and 
desensitisation. A lack of BDNF can certainly modify NMDA receptor function to a degree 
which induces depression [158], an interaction which may also account for the lower 
cognitive function which develops under omega-3-fatty acid deficiency [159].  
    There are several types of LTP in the hippocampus which can be loosely classified as 
associative and non-associative, both of which are influenced by BDNF. Associative forms of 
LTP can be potentiated by convergence of several inputs, involve NMDARs and have a 
postsynaptic component [124]. During induction of LTP, NMDARs are also known to be 
phosphorylated by a range of tyrosine kinases, one of which (the tyrosine kinase Fyn) is 
thought to play a major role in linking BDNF and NMDAR in the formation of spatial 
memory. The proposed mechanism involves BDNF stimulation of TrkB receptors which then 
associate with Fyn and cause it to bind to the Src homology 2 domains of NMDAR sub-units 
GluN2A and GluN2B [160]. This study employed the use of radial arm maze training to 
investigate the effects of spatial memory on phosphorylation of TrkB, Fyn, GluN2A and 
GluN2B in the rat hippocampus. Phosphorylation of all of these components, except sub-unit 
GluN2A, was stimulated by spatial learning and this was increased in trained rats. In 
addition, when Fyn was suppressed by administration of the tyrosine kinase inhibitor PP2 (4-
19 
 
amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-pyrazolo[3,4-d]-pyrimidine, which also reduced 
phosphorylation of GluN2B), there was a delay in memory acquisition before the rats reached 
the same level of learning as controls. This pharmacological blockade had no effect on TrkB 
phosphorylation. 
   Levels of BDNF can be elevated in response to exercise. The non-competitive NMDA 
receptor antagonist dizocilpine maleate (MK-801) induces schizophreniform symptoms in 
mice with changes in NMDAR expression and BDNF levels after treadmill exercise [161]. 
Dizocilpine treatment produced a decrease in NMDAR and BDNF, but a compensatory 
increase in response to treadmill exercise, raising the possibility of using exercise as a form 
of treatment in schizophrenia, working via BDNF and the regulation of NMDAR activity. 
 
Underlying mechanisms 
      Gut microbiota can synthesise and recognise an array of neurochemicals, including 
neurotransmitters, neuroactive short chain fatty acids (SCFAs), secondary bile acids and 
other biologically active small molecules. This could be the mechanism by which gut 
microbiota are able to directly influence neural systems in the host in a bidirectional manner. 
Several biosynthetic pathways present in eukaryotic cells exist in prokaryotic cells, probably 
as a result of gene transfer, providing a mechanism for this inter-species signalling [2,3]. The 
concept is supported by the discovery that Lactobacillus and Bifidobacterium spp. generate 
gamma-aminobutyric acid (GABA), Candida, Streptococcus, Escherichia and Enterococcus 
spp. synthesise 5-hydroxytrypamine (5-HT, or serotonin) and Bacillus spp. produce 
dopamine [48]. The serotonergic system of the brain develops abnormally in the absence of 
gut microbiota [139] highlighting the importance of these bacteria in neurodevelopment and 
emotional responses. Other neuroactive substances including histamine and adrenaline are 
also produced by microbiota. The presence of these agents in the intestinal lumen may 
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activate neural afferents or interact with chemosensitive epithelial cells or enterochromaffin 
cells which can then transmit sensory information regarding the luminal environment to the 
brain [2]. Therefore, neurotransmitters have been established as a possible route for 
microbiota to communicate with the gut-brain axis, with GABA and dopamine being of 
particular interest for their association with schizophrenia pathophysiology. 
   There is some evidence which indicates the involvement of SCFAs in the microbiota-gut-
brain axis. SCFAs are the end products of anaerobic fermentation of dietary fibre and starch 
in the large intestine and are absorbed primarily via the portal vein. Butyrate is an SCFA 
which acts as a colonic cell substrate and is known for its anti-inflammatory and anti-
carcinogenic properties [162], therefore playing an integral role in colonic health. Several 
studies have shown that sodium butyrate, a histone deacetylase inhibitor, has antidepressant-
like effects when administered as an epigenetic drug [163-166] and may be involved in 
neuropsychiatric conditions. Wei et al. [166] employed a rat model of depression to monitor 
the effects of sodium butyrate in relation to DNA methylation in the prefrontal cortex. These 
depressed mice possess decreased Ten-Eleven Translocation methylcytosine dioxygenase 1 
(TET1), which is the enzyme responsible for catalysing the conversion of DNA methylation 
to hydroxymethylation.  On administration of sodium butyrate, there was a reduction in 
depressive-like behaviour on the forced swim test and an elevation in TET1 levels. This 
positively correlated with a decrease in Bdnf methylation which subsequently caused an 
overexpression of BDNF. The findings indicate that the antidepressant effects of sodium 
butyrate may be caused by the associated elevation in BDNF which, as previously discussed, 
is thought to be diminished in schizophrenia and related mood disorders. 
     Another microbial fatty acid product with the potential to affect behaviour is propionic 
acid [69] although this has received less attention than butyrate.  A wide range of compounds 
generated by GI tract microbiota have direct or indirect effects on the brain and behaviour 
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[167]. Many of these compounds can target GABA receptors [168] in addition to the 
glutamate receptor modulation produced by tryptophan and its kynurenine metabolites 
discussed earlier.  
     A variety of amines can be produced which could cross the intestinal-vascular barriers in 
their uncharged form [169-174] including 5-hydroxytryptamine (serotonin) [175].  These 
compounds may arise directly from bacteria or indirectly from the actions of bacteria on 
dietary components [172,175-180]. Particularly interesting for this review is the compound 
lactoferrin which can alter BDNF expression [181], as well as immune modulators [182] and 
complex carbohydrates with implications for cellular energy metabolism [183,184]. Some of 
the compounds produced, such as claudin-2 [185], can affect barrier permeability and 
therefore the absorption of other, less permeable microbial products. A number of peptides 
originating in the GI tract can affect BDNF and thus, indirectly, behaviour. Pancreatic 
polypeptide, for example, acts on the hypothalamic appetite control centres to promote BDNF 
expression in the ventromedial satiety centre, ultimately modifying behaviour for food-
seeking [186]. Similarly, stimulation of synthesis and release of BDNF from intestinal cells 
by substance P and substance P and pituitary adenylate cyclase-activating peptide (PACAP) 
can indirectly affect behaviour [187]  
 
Developing novel therapeutics for schizophrenia  
   The data discussed in this review are not only relevant to future research into the aetiology 
of schizophrenia, but also indicate the potential for developing new anti-psychotic treatments 
as well as an earlier diagnosis of this disorder. In addition to targeting NMDARs directly 
through pharmacological intervention, novel ways to manipulate enteric bacteria, including 
probiotics, prebiotics and antimicrobial drugs, may hold the key to future treatment for 





   Probiotics provide a resource for altering the composition of gut microbiota though 
ingestion of live cultures. This approach is already popular for the amelioration of 
inflammatory bowel disease symptoms. GF mice displayed exaggerated stress and anxiety-
like behaviour compared to SPF mice [4] but, treated with Bifidobacterium infantis, these 
animals exhibited a complete normalisation of behaviour [188]. This not only reinforces the 
idea that the absence of gut microbiota was the cause of the stress and anxiety behaviour, but 
also introduces the prospect of using live cultures of healthy bacteria to maintain or restore a 
normal intestinal environment. 
   Beneficial effects of probiotics have also been reported in depression [74]. The rat maternal 
separation model is associated with up-regulation of the pro-inflammatory cytokine IL-6 in 
parallel with behavioural deficits and reduced levels of noradrenaline in the brain compared 
to controls. A reversal of all of these effects was observed following administration of B. 
infantis. This is highly significant as it shows that probiotics are effective in the treatment of 
depression in rats and this may have huge implications for human studies and in the treatment 
of a wide range of mood disorders, including schizophrenia. 
 
Prebiotics 
   Prebiotics are soluble sugars, such as fructo-oligosaccharide and galacto-oligosaccharide 
(GOS), which are ingested by commensal microbiota and promote their proliferation. This in 
turn influences gene expression of neurotransmitters and neuromodulators in the 
hippocampus, subsequently modulating neurodevelopment in mice [189]. Analysis of faecal 
pellets revealed an approximately 25% and 80% increase in Bifidobacteria in fructo-
oligosaccharide and GOS fed rats respectively, when compared to controls. There was also an 
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increase in hippocampal BDNF protein levels and expression of the NMDAR GluN1 sub-unit 
in response to prebiotic feeding as well as a significant increase in BDNF and GluN1 mRNA 
in the dentate gyrus. In addition, GOS ingestion specifically caused an increase in GluN2A 
sub-unit immunoreactivity and mRNA in the hippocampus with increased GluN1 expression 
and D-serine levels in frontal cortex. It was suggested that BDNF release may be associated 
with SCFAs or gut hormones such as peptide YY, as this hormone was found to be increased 
following GOS ingestion. Interestingly, these interactions can also be observed in vitro:  a 




   Antimicrobial agents affect the central levels of BDNF and behaviour in mice. Oral 
administration of non-absorbable antibiotics such as neomycin, bacitracin and pimaricin to 
SPF (but not GF) mice can increase hippocampal expression of BDNF [190].  This was 
accompanied by alterations in the composition of the gut microbiota (the putative cause of 
BDNF changes), including  an increase in Lactobacilli,  Firmicutes and Actinobacteria and a 
decrease in Proteobacteria and Bacteroidetes populations, accompanied by an increase in 
exploratory behaviour (the putative consequence of BDNF changes).  
     The altered behaviour was measured through standard step-down and light-dark 
preference tests in which mice treated with antibiotics had a shorter step down time and spent 
longer in the brighter compartment. It is important to note that these results were found to be 
independent of the autonomic nervous system, enteric neurotransmitters and inflammation. 
The microbial composition and behavioural changes were reversible and transferable: 
antibiotic effects were transient and normalised two weeks after withdrawal, and the 
24 
 
colonisation of GF mice with microbiota from different species conferred different 
behavioural phenotypes on the recipients.  
 
Diet, microbiota and behaviour 
     One final aspect of this topic arises from all that has been noted above. An individual’s 
natural diet will determine not only which microbiota gain entry to the alimentary canal, but 
also the degree of survival and balance between the different species, depending on the 
requirements and the extent of competition with other micro-organisms and the host. Since 
the microbiota clearly do play a significant role in defining the activity of the brain, it follows 
that there is likely to be some relationship between diet and mental health, with the possibility 
that manipulating dietary content could be a treatment or beneficial adjunct in the treatment 
of patients. It is certainly clear that patients with schizophrenia, for example, have a poor diet 
and low interest in dietary or culinary matters, with few unprocessed plant-based products 
[191-195]. The fat and calorie intake parallels the intensity of psychotic symptoms [196,197] 
and high-fat diets can counter aspects of schizophrenia-like behaviour in some animal models 
[198]. An especially instructive study by Gama et al. [199] showed that dietary 
supplementation with omega-3 fatty acids could prevent the behavioural, schizophrenia-like 
symptoms of animals treated with the NMDA antagonist ketamine. 
    Since BDNF is intimately involved in the regulation of food intake, dietary-induced 
obesity in animals alters the brain levels of BDNF as well as  food-seeking behaviour [135].  
Just as some probiotic bacteria can modify BDNF levels in the brain [143] and improve 
behavioural response to stress in parallel with increases in central BDNF levels [200-202], so 
specific patterns of food intake have been linked to behavioural changes [203] with altered 
BDNF production.  The carbohydrate and fat content is again particularly important [204] 
and patients with schizophrenia exhibit large increases in central BDNF in response to 
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feeding low calorific diets. High cereal diets have also been linked with psychotic behaviour 
[205] and specific dietary components such as curcumin [206] and polyphenols [203] have 
been identified as compounds mediating some of these effects [207].  
 
CONCLUSIONS  
      The studies discussed here indicate that gut microbiota harbour the ability to modulate 
levels of BDNF and NMDAR activity in the CNS. As BDNF is necessary for a range of 
neurodevelopmental and neuroprotective functions including synaptic plasticity, this has a 
significant impact on learning and memory, which is consistent with the reduced levels of 
BDNF in schizophrenia and other mood disorders [4,25,139]. LTP is thought to be the result 
of BDNF-mediated phosphorylation of NMDARs. A decrease in BDNF levels means less 
phosphorylation and a decreased ability to maintain normal levels of NMDAR activity, 
resulting in the receptor hypofunction that is now believed to be central to the development of 
schizophrenic symptoms. NMDAR hypofunction on GABA-releasing inhibitory interneurons 
causes disinhibition of glutamatergic output which modifies the signal-to-noise ratio and 
leads to abnormal patterns of network activity. This discordant firing manifests as a 
hyperdopaminergic state, which culminates in psychosis and cognitive deficits in 
schizophrenia, particularly through impairments in learning and memory. Perturbations in gut 
microbiota have a negative impact on BDNF levels, leading to NMDAR hypofunction and 
prebiotics, probiotics and antimicrobials are amongst the array of methods currently being 
investigated to normalise an abnormal microbial composition as potential anti-psychotic 
treatments. 
    Gaining a deeper insight into the routes by which gut microbiota are able to control the 
host CNS and manipulate it in a mutually beneficial way, will open new avenues into 
treatment for a wide range of disorders. Pinpointing the mechanisms which are disrupted in 
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psychiatric conditions such as schizophrenia will allow for the development of new drug 
targets. A normal microbial composition can be re-established following disruption by 
ingestion of pro- and pre-biotics, with huge implications in a world in which micro-organisms 
are increasingly tolerant and resistant to conventional antibiotic treatments. For example, it 
might be possible to treat brain disorders with a simple but effective drink containing live 
cultures, which has the benefit of increased patient compliance and ease of administration. 
The limitations which may be faced in this endeavour are primarily a result of the vast 
complexity of the microbiome and the fact that it is probably the overall mixture of 
microbiota which creates a chemical milieu which is unique to each individual patient.  
   It is important to note that the composition of microbiota and innervation of the GI tract are 
not homogeneous along the intestine. As a result, extensive research will be required to 
analyse the microbiome at different points along the gut to ascertain what is an overall 
‘normal’ population at each point. Information gathered from a particular section of GI tract 
can then be assessed in relation to the innervation of that section and the range of signalling 
pathways mediating the reciprocal influences of microbes and host cell function. This will aid 
metagenomic studies and allow for the identification of alterations seen in patients with 
schizophrenia and their physiological impact. In addition, it may be found that certain 
neuroactive molecules are only produced by certain species at certain points, that these 
substances only elicit an effect at specific sites or that these agents stimulate the epithelial 
cells which then release further molecules to elicit the observed effects. Since it is established 
that diet is a major factor determining the composition of bacteria in the gut it must be taken 
into consideration that microbiota may require certain substrates obtained though digestion 
for the synthesis of various products. This could cause significant differences between results 
obtained in vitro and in vivo preparations, which would need to be accounted for in any 
analysis intended to apply realistically to everyday activity. 
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     Overall this review has emphasised the role of GI microbiota on behaviour, BDNF levels 
and NMDAR function, involving bi-directional interactions between BDNF and NMDAR 
composition and function which together reveal a network that could underlie behavioural 
disorders in humans, such as depression and schizophrenia. This concept has major 
implications for understanding the origins and mechanisms of such disorders, but also for 
identifying future avenues for treatment by the modulation of the GI microbiome. On the 
wider landscape, many more disorders may involve changes in BDNF and could become 
amenable to interference with GI microbiota. Some long-standing example of how chronic 
diseases such as rheumatoid arthritis can be treated by dietary manipulation [208] may find 
explanation in these concepts. A loss of BDNF has even been demonstrated in the brains of 
patients with Huntington's disease, especially in the medium spiny neuron population of the 
striatum. Conversely, enhancing BDNF function improves brain structure and reduces 
behavioural deficits in mouse models of the disorder [209]. Together these data may imply 
that disease severity might be modulated by appropriate manipulation of the diet and GI 
microbiota. Similar considerations in other inherited conditions may show that even these 
disorders are susceptible to exacerbation or improvement by appropriate manipulation of the 
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Figure 1. Schematic summary of the main concepts. 
Panel A summarises the main premise that the microbial lining of the intestine, produce a 
variety of compounds which can penetrate the epithelium and affect the activity of immune 
cells and their production of cytokines and chemokines. Conversely cytokines from the white 
cells can modulate the viability and activity of the microbiota. The microbial factors 
ultimately reach the CNS where they are able to regulate neuronal activity and 
neurotransmission. 
Panel B focusses on the mechanisms mediating the microbial influence on CNS function and 
thus cognition and behaviour. Kynurenine and quinolinic acid, as well as tryptophan itself, 
synthesised by bacteria can cross the epithelial barrier and reach the CNS where kynurenine 
is converted to quinolinic acid, an NMDAR agonist, and kynurenic acid, a glutamate receptor 
blocker. The interaction between microbiota, intestinal epithelium and white cells affect the 
overall concentrations of several cytokines, which in turn modulates the synthesis of pro-
BDNF and BDNF. Pro-BDNF contributes to LTD and inhibits BDNF production, while 
BDNF increases NMDAR synthesis and functionality. NMDAR contribute to LTP but also 
depolarises GABA-releasing neurons that depress glutamatergic neurons. Superimposed on 
this is the effect of stress, illustrated as the induction of corticosteroid release which 
modulates the interaction between BDNF and NMDAR. Glucocorticoids also promote the 
conversion of tryptophan to kynurenine via their induction of tryptophan-2,3-dioxygenase 
(TDO). Exercise also increases BDNF production and so enhances cognitive function. 
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